Biotech Company Acquires Biopharmaceutical Company for $2.2 Billion

Represented Abgenix in sale to Amgen by negotiated merger agreement and proxy statement for approximately $2.2 billion. Read the press release.

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of fully human therapeutic antibodies.*